Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments - Segment Information (Details)

v3.21.1
Note 15 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Revenue from contract with customer $ 22,000 $ 15,000  
Grant and other revenue 101,251 141,051  
Revenues, Total 123,737 156,272  
Cost of revenue 609  
Research and development expenses 1,222,754 999,269  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 2,212,997 1,810,911  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 17,748 16,843  
Loss from operations [3] (3,329,762) (2,671,360)  
Other income (4) [4] 362,870 (2,248)  
Net loss (2,966,892) (2,673,608)  
Total assets, net of depreciation and amortization 10,077,075   $ 7,758,018
Capital expenditures 6,459  
UNITED STATES      
Total assets, net of depreciation and amortization 9,883,881 4,477,231  
Non-US [Member]      
Total assets, net of depreciation and amortization 193,194  
License [Member]      
Revenue from contract with customer 22,486  
Royalty [Member]      
Revenue from contract with customer 15,221  
Diagnostics Segment [Member]      
Grant and other revenue 101,251 58,916  
Revenues, Total 123,737 74,137  
Cost of revenue 609  
Research and development expenses 1,094,390 957,626  
Selling, general and administrative expenses, excluding depreciation and amortization [1]  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 6,040  
Loss from operations [3] (976,693) (884,098)  
Other income (4) [4]  
Net loss (976,693) (884,098)  
Capital expenditures  
Diagnostics Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 160,669 36,671  
Diagnostics Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization 193,194  
Diagnostics Segment [Member] | License [Member]      
Revenue from contract with customer 22,486    
Diagnostics Segment [Member] | Royalty [Member]      
Revenue from contract with customer   15,221  
Therapeutics Segment [Member]      
Grant and other revenue 82,135  
Revenues, Total 82,135  
Cost of revenue  
Research and development expenses 128,364 41,643  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 2,006 (1,522)  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
Loss from operations [3] (130,370) 42,014  
Other income (4) [4]  
Net loss (130,370) 42,014  
Capital expenditures  
Therapeutics Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 2,494  
Therapeutics Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization  
Therapeutics Segment [Member] | License [Member]      
Revenue from contract with customer    
Therapeutics Segment [Member] | Royalty [Member]      
Revenue from contract with customer    
Corporate Segment [Member]      
Grant and other revenue  
Revenues, Total  
Cost of revenue  
Research and development expenses  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 2,210,991 1,812,433  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 11,708 16,843  
Loss from operations [3] (2,222,699) (1,829,276)  
Other income (4) [4] 362,870 (2,248)  
Net loss (1,859,829) (1,831,524)  
Capital expenditures 6,459  
Corporate Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 9,723,212 4,438,066  
Corporate Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization  
Corporate Segment [Member] | License [Member]      
Revenue from contract with customer    
Corporate Segment [Member] | Royalty [Member]      
Revenue from contract with customer    
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($17,748 and $16,843 for the three-month periods ended March 31, 2021 and 2020, respectively).
[3] Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4] Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.